This company has been marked as potentially delisted and may not be actively trading. NASDAQ:MDCO Medicines (MDCO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Medicines Stock (NASDAQ:MDCO) 30 days 90 days 365 days Advanced Chart Get Medicines alerts:Sign Up Key Stats Today's Range$84.90▼$84.9050-Day Range$84.90▼$84.9052-Week Range$17.81▼$84.98VolumeN/AAverage Volume9.55 million shsMarket Capitalization$6.77 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview The Medicines Company, a biopharmaceutical company, focuses on developing therapeutics for the treatment of therosclerotic cardiovascular disease. The company is developing Inclisiran, an investigational RNA interference therapeutic that inhibits production of proprotein convertase subtilisin/kexin type 9, which controls LDL-cholesterol levels. It has collaboration agreement with Alnylam Pharmaceuticals, Inc. The Medicines Company was founded in 1996 and is headquartered in Parsippany, New Jersey. Read More Receive MDCO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medicines and its competitors with MarketBeat's FREE daily newsletter. Email Address MDCO Stock News HeadlinesTYK Medicines, Inc. Explores Distribution Partnership for TY-9591August 26 at 8:51 AM | tipranks.comBeOne Medicines: Brukinsa's Leadership And Royalty Sale Signal A Stronger FutureAugust 26 at 8:50 AM | seekingalpha.comA Major Economic Change Is Happening NowLouis Navellier is one of Wall Street’s most respected money managers — overseeing more than $7 billion and earning a reputation for fact-based analysis, not sensationalism. That’s why his latest economic warning is turning so many heads. In his new report, Louis reveals how recent policies are accelerating a massive economic shift. While headlines point to strong numbers, everyday Americans feel the squeeze as prices climb and industries are reshaped. According to Louis, this transformation could determine who falls behind — and who builds lasting wealth.August 26 at 2:00 AM | InvestorPlace (Ad)Praxis Precision Medicines to Present Recent Epilepsy Study Results at International Epilepsy Congress 2025August 25 at 4:31 PM | quiverquant.comQBeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 MillionAugust 25 at 7:10 AM | gurufocus.comBeOne Medicines Ltd (ONC) Announces $950 Million Royalty Rights Sale to Royalty Pharma | ONC ...August 25 at 7:10 AM | gurufocus.comBeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 MillionAugust 25 at 6:31 AM | mms.businesswire.comBeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million | ONC ...August 25 at 6:30 AM | gurufocus.comSee More Headlines MDCO Stock Analysis - Frequently Asked Questions How were Medicines' earnings last quarter? The Medicines Company (NASDAQ:MDCO) announced its earnings results on Wednesday, October, 30th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by $0.12. What other stocks do shareholders of Medicines own? Based on aggregate information from My MarketBeat watchlists, some other companies that Medicines investors own include Bristol Myers Squibb (BMY), NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU), AbbVie (ABBV), Alibaba Group (BABA) and Salesforce (CRM). Company Calendar Last Earnings10/30/2019Today8/26/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:MDCO CIK1113481 Webwww.themedicinescompany.com Phone973-290-6000FaxN/AEmployees62Year FoundedN/AProfitability EPS (Trailing Twelve Months)($2.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$123.16 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-25.70% Debt Debt-to-Equity Ratio21.45 Current Ratio0.77 Quick Ratio0.77 Sales & Book Value Annual Sales$6.14 million Price / Sales1,102.36 Cash FlowN/A Price / Cash FlowN/A Book Value($0.30) per share Price / Book-283.00Miscellaneous Outstanding Shares79,723,000Free FloatN/AMarket Cap$6.77 billion OptionableOptionable Beta1.10 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:MDCO) was last updated on 8/26/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 30th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding The Medicines Company Please log in to your account or sign up in order to add this asset to your watchlist. Share Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access